Blue Pool Capital

Founded 2004

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 12
Average round size
info
The average size of a deal this fund participated in
$93M
Portfolio companies 10
Rounds per year 0.71
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 2
Key employees 5
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Life Science
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Blue Pool Capital:
Typical Co-investors
Blue Pool Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Blue Pool Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China, Hong Kong Island
Funds with similar focus located in China, Hong Kong Island:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
RoseRock United States, Bryan
The MasterCard Foundation Canada, Toronto
LSP BioVentures United States, Cambridge
China Reinsurance Group China, Beijing
MGM Studios United States, Beverly Hills
Beijing Huadian Shidai Technology Development China, Beijing
Hangzhou Yongyuan China, Hangzhou
Tibet Kexin Venture Investment Partnership (L.P.) China, Lhasa
Beijing Zhiyun Asset Management China, Beijing Shi
Ai Hexin Touzi China, Shenyang

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Animoca Brands

Apps
Casual Games
Developer Platform
Gaming
Mobile
n/a
$50M01 Jul 2021 China, Hong Kong Island

Fog Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
1
$107M11 Jan 2021 Cambridge Massachusetts United States

LifeMine Therapeutics

Biotechnology
Life Science
Therapeutics
1
$50M07 Jan 2021 Cambridge Massachusetts United States

Computer
eSports
Gaming
PC Games
1
$10M30 Oct 2020 California Los Angeles United States

Brii Biosciences

Biotechnology
Health Care
Innovation Management
Pharmaceutical
1
$260M24 May 2018 California San Francisco United States

Grail

Biotechnology
Health Care
Health Diagnostics
Medical
Medical Device
1
$300M21 May 2018 California United States

Fog Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
1
$66M16 May 2018 Cambridge Massachusetts United States

Hua Medicine

Biotechnology
Health Care
Life Science
Medical
Pharmaceutical
1
$117M27 Mar 2018 China Shanghai

Rent the Runway

Consumer Goods
E-Commerce
Fashion
Retail
1
$20M09 Mar 2018 New York United States
News
NEX raises $25M, launches Active Arcade to get people moving

– NEX, a motion entertainment startup, raised $25m funding.
– The round was led by Blue Pool Capital and joined by Samsung Ventures, SparkLabs and Susquehanna.
– It brings NEX to a valuation of $100m.
– The company is building motion entertainment – content that encourages physical movement.

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Blue Pool Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: